Providers

The Center on Health Equity & Access highlights news and expert insights on research, social determinants of health, and health policy.

The findings show that increases in serum glial fibrillary acidic protein throughout B-cell depletion therapy are associated with disability worsening despite not relapsing—known as progression independent of relapse activity.

With ponatinib (Iclusig) receiving an accelerated approval from the FDA earlier this year for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), updated guidelines could be on the horizon.

The 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report highlighted climate change, cardiovascular risk, and pulmonary hypertension.

If made official, the proposed rule would give Part D and Medicaid beneficiaries expanded coverage to antiobesity drugs starting in 2026.

The FDA approval marks the first oral solution indicated for patients with different forms of leukemia.

For some patients with myasthenia gravis (MG), activity and sleep were associated with reported fatigue and symptom levels.

A new study shows that COVID-19 infection significantly increases the risk of exacerbation in patients with myasthenia gravis (MG).

Coverage from the IVBM Regional event in Denver, Colorado.

Long-term survival rates for patients with leukemia after hematopoietic cell transplantation (HCT) are encouraging but personalized transplant strategies remain important to improve outcomes.

The SARAH trial was limited to high-risk patients, which the lead investigator said prevented unnecessary exposure to adverse events in patients less at risk of cardiomyopathy.

New study findings reveal that the risk of cardiovascular disease among light ex-smokers aligns quickly with never-smokers, while heavy ex-smokers may take over 25 years to reach the same level.

Put up against placebo in the phase 3 EMBARK trial, delandistrogene moxeparvovec (Elevidys) did not significantly improve function after 52 weeks.

Findings of a recent study indicate that NUP98 rearrangements can significantly impact outcomes in patients with acute myeloid leukemia (AML).

New and in-the-pipeline Janus kinase (JAK) inhibitors have the potential to make huge differences in the lives of patients with this psychologically distressing autoimmune disease.

Investigators used 3-dimensional quantitative computed tomography to more accurately assess patients’ bone mineral density.

Lindsay Bealor Greenleaf, JD, MBA, of ADVI Health, weighs in on what to expect in key health care policy areas in the wake of the election.

The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options for patients with idiopathic pulmonary fibrosis (IPF).

Authors found the pharmacy costs for momelotinib were $11,095 higher per month, too much to offset higher transfusion costs for ruxolitinib.

The Quadruple Aim—a framework originally rooted in improving patient experience, enhancing population health, and achieving cost savings—has evolved to include a fourth dimension: provider well-being.

Physician reimbursement stands to be affected by the consolidation of medical systems and changes in Medicare enrollment affecting their pay, which may lead to shifts in medical training and hiring.

Brendon Yee, PhD, professor and respiratory and sleep physician, Woolcock Institute of Medical Research, discusses the success of ALKS 2680, an investigational oral selective orexin 2 receptor agonist.

The future of hemophilia care lies not only in technological advancements but also in the pursuit of health equity, ensuring that all patients have access to effective, affordable treatments.

The gene therapy improved annualized bleed rates, though a handful of study participants resumed factor IX prophylaxis.

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, particularly regarding immune-related adverse events.

Although polycythemia vera management remains focused on reducing the risk of thrombotic events, there is growing recognition of the need to address the persistent decline in quality of life experienced by many patients.

New treatments for Alzheimer disease don’t reverse cognitive symptoms, but they do significantly slow progression. Evidence suggests that earlier treatment is most effective.

Symptomatic improvement on therapy for myeloproliferative neoplasms (MPNs) is very much based on the individual. Data does show momelotinib not only improved spleen size and anemia but also improved symptomatic burden.